Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Rigby

Showing results (161-170 of 167) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 167 results.
Circulation|August 4, 2011
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsiaRavi Thadhani, Tuelay Kisner, Henning Hagmann, et al.
Molecular Cancer Therapeutics|September 4, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2-Targeting Agents Results from Kinase ActivationFeven Tameire, Paulina Wojnarowicz, Crissy Dudgeon, et al.
Molecular Cancer Therapeutics|August 20, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2 Targeting Agents Results from Kinase ActivationFeven Tameire, Paulina Wojnarowicz, Crissy Dudgeon, et al.
Annals of the Rheumatic Diseases|January 16, 2021
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trialRené Westhovens, William F C Rigby, Désirée van der Heijde, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G Thomson, Thomas D Aicher, Weiwei Cheng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk IndividualsMarije K Verheul, Stefan Böhringer, Myrthe A M van Delft, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2021
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitorsVeronica Calvo, David Surguladze, An-Hu Li, et al.
Pageof 17

Showing results (161-170 of 167) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 167 results.
Circulation|August 4, 2011
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsiaRavi Thadhani, Tuelay Kisner, Henning Hagmann, et al.
Molecular Cancer Therapeutics|September 4, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2-Targeting Agents Results from Kinase ActivationFeven Tameire, Paulina Wojnarowicz, Crissy Dudgeon, et al.
Molecular Cancer Therapeutics|August 20, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2 Targeting Agents Results from Kinase ActivationFeven Tameire, Paulina Wojnarowicz, Crissy Dudgeon, et al.
Annals of the Rheumatic Diseases|January 16, 2021
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trialRené Westhovens, William F C Rigby, Désirée van der Heijde, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G Thomson, Thomas D Aicher, Weiwei Cheng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk IndividualsMarije K Verheul, Stefan Böhringer, Myrthe A M van Delft, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2021
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitorsVeronica Calvo, David Surguladze, An-Hu Li, et al.
Pageof 17